Abstract:The goal of this study is to identify RNA interference (RNAi) seed sequences that inhibit androgen signaling and induce toxicity in prostate cancer (PCa) cells. The high prevalence of acquired resistance to androgen deprivation therapy, as well as first and second generation androgen receptor (AR) antagonists, drives the development of lethal castration resistant prostate cancer (CRPC). As a result, PCa remains one of the leading causes of cancer related deaths in men. AR amplification, gain of function mutations and constitutively active splice isoforms of the AR, and the overexpression of AR coregulators, play considerable roles in promoting CRPC by sustaining AR activity in the presence of the low androgen environment and/or AR antagonists. The development of specific small molecule inhibitors of AR splice isoforms has been largely unsuccessful, and inhibitors of individual AR coregulators have not translated well into the clinic, likely due to their large number and functional redundancies. Therefore, novel therapeutic strategies for targeting androgen signaling in CRPC are necessary. Previous studies in our lab have demonstrated RNAi-mediated PCa cell death through seed region (nucleotides 2-8) complementarity of shRNA/siRNA guide strands to the 3'UTR of the AR and multiple AR coregulators and essential genes. In the current study, we used an unbiased novel seed-based shRNA screen to identify seed sequences that are toxic to different PCa cells, including CRPC cells expressing the clinically relevant constitutively active AR variant 7 (AR-V7). Common motifs were identified among toxic seed sequences, and the miRDB target prediction database was used to select those seeds that were predicted to target the AR and AR coregulators. Using RNA-seq analyses we confirmed that selected seed sequences inhibited global androgen signaling and identified potential direct targets known to be relevant to PCa. Conclusions: These studies have identified androgen signaling inhibitory sequences that have the potential to be used in RNAi-seed based therapies for PCa. The ability to inhibit the expression of the AR and multiple essential AR coregulators simultaneously with one agent, and the reduced likelihood of developed resistance, are considerable benefits of this approach. Citation Format: Joshua M. Corbin, Maria J. Ruiz-Echevarria. RNA interference seed-based approach to inhibit androgen signaling and induce prostate cancer cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1483.

Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

The Growth Inhibition Effects on Prostate Cancer Cells by Blocking Expression of Androgen Receptor with Antisense Oligonucleotide

Proliferative Response of Human Prostate Cancer Cell to Hormone Inhibited by Androgen Receptor Antisense RNA

Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy

Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours

Transcriptional suppression of androgen receptor by 18β-glycyrrhetinic acid in LNCaP human prostate cancer cells

Inhibition of Prostate Cancer Cells with Antisense RNA of Ornithine Decarboxylase Gene

Identification of Novel Androgen Receptor Degrading Agents to Treat Advanced Prostate Cancer

Prostate-targeted Biodegradable Nanoparticles Loaded with Androgen Receptor Silencing Constructs Eradicate Xenograft Tumors in Mice

Novel Small‐molecule LG1836 Inhibits the in Vivo Growth of Castration‐resistant Prostate Cancer

Abstract 1483: RNA interference seed-based approach to inhibit androgen signaling and induce prostate cancer cell death

Adeno-Associated Virus-Delivered Short Hairpin-Structured Rna For Androgen Receptor Gene Silencing Induces Tumor Eradication Of Prostate Cancer Xenografts In Nude Mice: A Preclinical Study

Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer

Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer

A Novel Androgen Receptor (ar) Suppressor Complex (Ars)-an Essential Factor in Androgen-Independent Progression of Prostate Cancer (Pc)

Targeting Silencing Androgen Receptor Gene by Shrna with Low-Intensity Focused Ultrasonic Irradiation Inhibits Growth of Prostate Cancer Xenografts in Nude Mice.

Data from Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer

LINC00675 Activates Androgen Receptor Axis Signaling Pathway to Promote Castration-Resistant Prostate Cancer Progression

Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells

A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

Targeting Androgen Receptor Versus Targeting Androgens to Suppress Castration Resistant Prostate Cancer.